In vitro study of FUZ as a novel potential therapeutic target in non-small-cell lung cancer

Area of Science:

• Molecular Biology
• Cancer Biology
• Cell Biology

Background:

• FUZ (Fuzzy) is a planar cell polarity effector crucial for vertebrate development.
• Its role in tumor biology, particularly in non-small cell lung cancer (NSCLC), is largely unexplored.

Purpose of the Study:

• To investigate the physiological effects and underlying mechanisms of FUZ in non-small cell lung cancer (NSCLC) in vitro.
• To determine FUZ's potential as a therapeutic target for NSCLC.

Main Methods:

• Bioinformatics analysis to correlate FUZ expression with NSCLC patient prognosis.
• In vitro experiments involving exogenous FUZ expression and FUZ-directed siRNA treatments in NSCLC cells.
• Analysis of cell proliferation, migration, signaling pathways (Erk1/2, STAT3), epithelial to mesenchymal transition (EMT) markers, and BNIP3 protein levels.

Main Results:

• FUZ expression negatively correlates with NSCLC patient prognosis.
• Overexpression of FUZ promotes NSCLC cell proliferation, activates Erk1/2 and STAT3 signaling, and enhances cell motility.
• FUZ induces epithelial to mesenchymal transition (EMT) by upregulating N-cadherin, vimentin, Zeb1, and Twist1, while downregulating E-cadherin.
• FUZ interacts with BNIP3, and its loss decreases BNIP3 protein stability.
• Knockdown of FUZ inhibits cell growth, migration, and reverses EMT.

Conclusions:

• FUZ drives NSCLC progression and metastasis through signaling pathway activation and EMT induction.
• FUZ's interaction with BNIP3 affects protein stability.
• FUZ represents a potential therapeutic target for non-small cell lung cancer.